Darier disease
ICD-10 Q82.8 · ICD-11 EC20.2

Localized Darier Disease: What to Do When Supportive Care Fails to Improve Pruritus and Skin Irritation

Clinical Scenario

This protocol addresses patients with Darier disease whose skin involvement is localized — not disseminated or generalized — and who have not achieved adequate relief with first-line supportive and symptomatic management.

When First-Line Management Falls Short

Initial management of localized Darier disease typically includes supportive and symptomatic care: emollients, soap substitutes, cotton clothing, photoprotection, and careful avoidance of exacerbating factors. When this approach fails to achieve improvement of pruritus and skin irritation, a more targeted treatment step is indicated.

Treatment Approach (Partial Preview)

The evidence-based regimen for this scenario involves topical retinoids — a class with published clinical data specifically in localized Darier disease. The full protocol specifies agent selection, concentrations, duration, and whether adjunctive topical therapy is appropriate.

Treatment Goals

Complete resolution of symptoms and marked improvement of skin lesions.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.25259/IJDVL_963_19

For localized and resistant skin lesions, physical therapies including surgical excision, dermabrasion and CO2 laser ablation were the first line choices.

In 16 patients with a mean age of 43 (half of which were males), a formulation of 0.05% applied twice daily for 3 months was used.

Formulations of 0.1% isotretinoin were used by 3 patients for 1 to 3 months, with complete resolution of symptoms in 1 patient.

A total of 4 women with a mean age of 45 years used Tazarotene 0.05% and 0.1% daily with complete resolution of their symptoms.

Adapalene gel, a synthetic retinoid, was used in a total of 3 patients at a concentration of 0.1% daily for 2 months; all showed marked improvement with no side effects.

They have mostly been used in association with retinoids to reduce irritation.

Of those, 6 (35%) patients showed complete resolution of symptoms with only 1 patient experiencing a relapse following a month of treatment discontinuation.

View source ↗